CD80/CD28 co-stimulation in human brucellosis

Clinical and Experimental Immunology

Volumn 146, Issue 3, 2006, Pages 400-408

  Skendros, P ^a   Boura, P ^a   Kamaria, F ^b   Raptopoulou Gigi, M ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Infectious Diseases Hospital of Thessaloniki   (Greece)

Author keywords

Brucellosis; CD28; CD80; Co stimulation; Immune response

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; PHYTOHEMAGGLUTININ;

ADULT; ARTICLE; BRUCELLA ABORTUS; BRUCELLOSIS; CD4+ CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; RELAPSE; UPREGULATION;

ACUTE DISEASE; ADULT; ANTIGENS, CD28; ANTIGENS, CD80; BRUCELLOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHRONIC DISEASE; FEMALE; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; MONOCYTES; PHYTOHEMAGGLUTININS; T-LYMPHOCYTE SUBSETS;

EID: 33750859701     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03223.x     Document Type: Article

References (54)

1. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med 2005; 352:2325-36.
2. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis 2006; 6:91-9.
3. Bossi P, Tegnell A, Baka A et al. Bichat guidelines for the clinical management of brucellosis and bioterrorism-related brucellosis. Euro Surveill 2004; 9:E15-16.
4. Memish ZA, Balkhy HH. Brucellosis and international travel. J Travel Med 2004; 11:49-55.
5. Gotuzzo E, Carrillo C. Brucella. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases, 2nd edn. Philadelphia: W. B. Saunders, 1998:1837-45.
6. Berbari EF, Wilson WR. Brucella, Francisella, Pasteurella, Yersinia, and HACEK. In: Wilson WR, Sande MA, eds. Current diagnosis and treatment in infectious diseases. New York: McGraw-Hill, 2001:630-1.
7. Jimenez de Bagues MP, Dudal S, Dornand J, Gross A. Cellular bioterrorism: how Brucella corrupts macrophage physiology to promote invasion and proliferation. Clin Immunol 2005; 114:227-2.
8. Schaible UE, Collins HL, Kaufmann SH. Confrontation between intracellular bacteria and the immune system. Adv Immunol 1999; 71:267-377.
9. Golding B, Scott DE, Scharf O et al. Immunity and protection against Brucella abortus. Microbes Infect 2001; 3:43-8.
10. Yingst S, Hoover DL. T cell immunity to brucellosis. Crit Rev Microbiol 2003; 29:313-31.
11. + T cells express Th1-like cytokine mRNA and proteins following in vitro stimulation with heat-inactivated Brucella abortus. Infect Immun 1995; 63:2720-8.
12. Giambartolomei GH, Delpino MV, Cahanovich ME et al. Diminished production of T helper 1 cytokines correlates with T cell unresponsiveness to Brucella cytoplasmic proteins in chronic human brucellosis. J Infect Dis 2002; 186:252-9.
13. Zacharioudaki E, Boura P, Kountouras I, Skendros P, Lefkos N. Cytokine regulation and establishment of chronicity in brucellosis. EFIS 2003 Immunol Lett 2003; 87:51 [Abstract].
14. Kinikli S, Turkcapar N, Kucukay MB, Keskin G, Kinikli G. In vitro nonspecific mitogenic response of T-cell subsets in acute and chronic brucellosis. Diagn Microbiol Infect Dis 2005; 52:229-33.
15. + T-lymphocytes expressing interleukin-2 receptor alpha in chronic brucellosis. J Infect 2006; 20 May [Epub ahead of print].
16. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14:233-58.
17. Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996; 335:1369-77.
18. Harris NL, Ronchese F. The role of B7 costimulation in T-cell immunity. Immunol Cell Biol 1999; 77:304-11.
19. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003; 3:939-51.
20. Kuchroo VK, Das MP, Brown JA et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80:707-18.
21. Agranovich I, Scott DE, Terle D, Lee K, Golding B. Downregulation of Th2 responses by Brucella abortus, a strong Th1 stimulus, correlates with alterations in the B7.2-CD28 pathway. Infect Immun 1999; 67:4418-26.
22. Zhang P, Martin M, Yang QB, Michalek SM, Katz J. Role of B7 costimulatory molecules in immune responses and T-helper cell differentiation in response to recombinant HagB from Porphyromonas gingivalis. Infect Immun 2004; 72:637-44.
23. Zaitseva M, Golding H, Manischewitz J, Webb D, Golding B. Brucella abortus as a potential vaccine candidate: induction of interleukin-12 secretion and enhanced B7.1 and B7.2 and intercellular adhesion molecule 1 surface expression in elutriated human monocytes stimulated by heat-inactivated B. abortus. Infect Immun 1996; 64:3109-17.
24. Kaye PM. Costimulation and the regulation of antimicrobial immunity. Immunol Today 1995; 16:423-7.
25. Agrewala JN, Kumar B, Vohra H. Potential role of B7-1 and CD28 molecules in immunosuppression in leprosy. Clin Exp Immunol 1998; 111:56-63.
26. +) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein. Int Immunopharmacol 2004; 4:1-14.
27. Mariotti S, Teloni R, Iona E et al. Mycobacterium tuberculosis subverts the differentiation of human monocytes into dendritic cells. Eur J Immunol 2002; 32:3050-8.
28. Singh B, Singh G, Trajkovic V, Sharma P. Intracellular expression of Mycobacterium tuberculosis-specific 10-kDa antigen downregulates macrophage B7.1 expression and nitric oxide release. Clin Exp Immunol 2003; 134:70-7.
29. Gong JH, Zhang M, Modlin RL et al. Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA-4 expression. Infect Immun 1996; 64:913-8.
30. Corominas M, Cardona V, Gonzalez L et al. B-lymphocytes and co-stimulatory molecules in Mycobacterium tuberculosis infection. Int J Tuberc Lung Dis 2004; 8:98-105.
31. Caldwell CW, Taylor HM. A rapid, no-wash method for immunophenotypic analysis by flow cytometry. Am J Clin Pathol 1986; 86:600-7.
32. Ahmed K, Al-Matrouk KA, Martinez G, Oishi K, Rotimi VO, Nagatake T. Increased serum levels of interferon-gamma and interleukin-12 during human brucellosis. Am J Trop Med Hyg 1999; 61:425-7.
33. Demirdag K, Ozden M, Kalkan A, Godekmerdan A, Sirri Kilic S. Serum cytokine levels in patients with acute brucellosis and their relation to the traditional inflammatory markers. FEMS Immunol Med Microbiol 2003; 39:149-53.
34. Rafiei A, Ardestani SK, Kariminia A, Keyhani A, Mohraz M, Amirkhani A. Dominant Th1 cytokine production in early onset of human brucellosis followed by switching towards Th2 along prolongation of disease. J Infect 2006; 16 February [Epub ahead of print].
35. Dobrovolskaia MA, Vogel SN. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect 2002; 4:903-14.
36. Fujihara M, Muroi M, Tanamoto K, Suzuki T, Azuma H, Ikeda H. Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol Ther 2003; 100:171-94.
37. Ayaslioglu E, Tekeli E, Birengel S. Significant elevation of serum soluble CD14 levels in patients with brucellosis. Jpn J Infect Dis 2005; 58:11-4.
38. Abbas AK, Lichtman AH. Cellular and molecular imuunology, 5th edn. Philadelphia: W. B. Saunders, 2003.
39. Boura P, Skendros P, Kountouras J, Zacharioudaki E, Tsapas T. Effect of bacterial extracts on the immunologic profile in chronic relapsing brucellosis patients. Int J Immunopathol Pharmacol 1999; 12:103-11.
40. Thornes RD, Early AM, Hogan BL, Reen D. Chronic brucellosis - clinical response to reduction of suppressor T lymphocytes by cyclophosphamide/ prednisone. Ir Med J 1982; 75:423-4.
41. Moreno-Lafont MC, Lopez-Merino A, Lopez-Santiago R. Cell response to a salt-extractable and sonicated Brucella melitensis 16M antigen in human brucellosis. Clin Diagn Lab Immunol 1995; 2:377-80.
42. + T lymphocytes from brucellosis patients. Trans R Soc Trop Med Hyg 2002; 96:340-7.
43. lo T lymphocytes control intracellular Brucella abortus infection as demonstrated in major histocompatibility complex class I- and class II-deficient mice. Eur J Immunol 1995; 25:2551-7.
44. Inoue S, Golding B, Scott D. Programming of CTL with heat-killed Brucella abortus and antigen allows soluble antigen alone to generate effective secondary CTL. Vaccine 2005; 23:1730-8.
45. Sansom DM, Manzotti CN, Zheng Y. What's the difference between CD80 and CD86? Trends Immunol 2003; 24:314-9.
46. Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 2004; 21:401-13.
47. Bhatia S, Edidin M, Almo SC, Nathenson SG. B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties. Immunol Lett 2006; 104:70-5.
48. Lapaque N, Moriyon I, Moreno E, Gorvel JP. Brucella lipopolysaccharide acts as a virulence factor. Curr Opin Microbiol 2005; 8:60-6.
49. Martinez de Tejada G, Pizarro-Cerda J, Moreno E, Moriyon I. The outer membranes of Brucella spp. are resistant to bactericidal cationic peptides. Infect Immun 1995; 63:3054-61.
50. Fernandez-Prada CM, Zelazowska EB, Nikolich M et al. Interactions between Brucella melitensis and human phagocytes: bacterial surface O-polysaccharide inhibits phagocytosis, bacterial killing, and subsequent host cell apoptosis. Infect Immun 2003; 71:2110-9.
51. Rittig MG, Kaufmann A, Robins A et al. Smooth and rough lipopolysaccharide phenotypes of Brucella induce different intracellular trafficking and cytokine/chemokine release in human monocytes. J Leukoc Biol 2003; 74:1045-55.
52. Fernandez-Prada CM, Nikolich M, Vemulapalli R et al. Deletion of wboA enhances activation of the lectin pathway of complement in Brucella abortus and Brucella melitensis. Infect Immun 2001; 69:4407-16.
53. Kariminia A, Kavoossy G, Khatami S, Zowghi E, Ardestani SK. Study of interleukin-10 and interleukin-12 productions in response to lipopolysaccharides extracted from two different Brucella strains. Comp Immunol Microbiol Infect Dis 2002; 25:85-93.
54. Dornand J, Gross A, Lafont V, Liautard J, Oliaro J, Liautard JP. The innate immune response against Brucella in humans. Vet Microbiol 2002; 90:383-94.